From systemic to CNS, Highlightll leads the next breakthrough in inflammation.

Highlightll is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of autoimmune and inflammatory diseases across both peripheral and central nervous systems. By integrating global resources with deep in-house expertise, we aim to address some of the most challenging unmet medical needs in immunology and neuroinflammation.

Our pipeline is built on two highly differentiated platforms.

The first is our dual JAK1/TYK2 inhibition platform, where Highlightll has established global leadership. TLL-041, the world’s first brain-penetrant JAK1/TYK2 inhibitor, represents a first-in-class approach for CNS inflammation and was licensed to Biohaven in 2023. The program has since advanced to a global Phase II/III pivotal trial in Parkinson’s disease under Biohaven (BHV-8000/TLL-041).

Our most advanced program, TLL-018, is a peripherally acting JAK1/TYK2 inhibitor and one of the fastest-progressing assets in autoimmune diseases. It is currently in Phase III trials for chronic spontaneous urticaria (CSU) and rheumatoid arthritis (RA), with positive interim Phase III data in CSU. To date, TLL-018 has been evaluated in more than 1,000 patients across China and the United States.

Our second platform focuses on NLRP3 inflammasome inhibition, targeting both central and peripheral inflammatory diseases. HL-400, our brain-penetrant NLRP3 inhibitor for neurodegenerative diseases, is among the most advanced CNS-penetrant NLRP3 programs globally, while HL-450 addresses peripheral inflammatory indications.

Together, Highlightll is pioneering a new generation of therapies that bridge systemic and CNS inflammation, with the ambition to deliver truly breakthrough medicines for patients worldwide.

Highlightll Pharma

Org chart

Teams

Offices

Highlightll Pharma

Org chart

Teams

Offices

Related companies